rVSVΔG-ZEBOV (Immediate Vaccination) vs rVSVΔG-ZEBOV (Deferred Vaccination): Suspected, Probable or Laboratory-confirmed Ebola
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00634 | 0.00436 | 0.0092 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00449 | 0.0028 | 0.00718 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00185 | -0.00149 | 0.00517 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.771 | 2.59 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.41 | 0.77 | 2.6 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on rVSVΔG-ZEBOV (Immediate Vaccination) than on rVSVΔG-ZEBOV (Deferred Vaccination) | 541 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | rVSVΔG-ZEBOV (Immediate Vaccination) | One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10\^7 plaque forming units)~rVSVΔG-ZEBOV: The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain). | 27 | 4,261 | OG000 | ClinicalTrials.gov |
| Group 2 | rVSVΔG-ZEBOV (Deferred Vaccination) | One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10\^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).~rVSVΔG-ZEBOV: The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain). | 17 | 3,788 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Suspected, Probable or Laboratory-confirmed Ebola | ClinicalTrials.gov |
| Description | Incidence of suspected, probable, or laboratory-confirmed Ebola, where suspected and probable cases are defined by the August 9, 2014 World Health Organization case definition recommendations for use during an Ebola outbreak, and laboratory-confirmed Ebola includes both study laboratory and non-study laboratory diagnostics. An Ebola Screening Form was required to be completed for all participants referred for evaluation of suspected Ebola; the Outcome Measure (Count of Participants) reflects the number of participants in each group for whom an Ebola Screening Form was completed. | ClinicalTrials.gov |
| Time frame | 6 months following vaccination | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) | ClinicalTrials.gov |
| NCT number | NCT02378753 | ClinicalTrials.gov |
| Phases | PHASE2, PHASE3 | ClinicalTrials.gov |
| Conditions | Hemorrhagic Fever, Ebola | ClinicalTrials.gov |
| Interventions | rVSVΔG-ZEBOV | ClinicalTrials.gov |
| Lead sponsor | Centers for Disease Control and Prevention | ClinicalTrials.gov |
| Results first posted | 2018-04-05 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02378753?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.